HIMS Squeezes Through the 200-Week Moving Average With 46% of Float Short

The Setup

HIMS had every ingredient for a squeeze before the move started. Short interest climbed to 84.96 million shares — 46.09% of available float — with a days-to-cover ratio of 2.58 based on average volume. S3 Partners flagged the squeeze score at 100, the maximum reading on their scale, meaning any sustained buying pressure would mechanically force short covering.

Traders on X noted HIMS recaptured the 200-week moving average on April 13 with a 10% session, the kind of technical level that attracts systematic buyers and stops out shorts simultaneously. By Tuesday's close, the stock printed $24.33 — up 13.88% on 40.8 million shares, well above average daily volume.

This is not the first time HIMS shorts have been punished. In March, the Novo Nordisk settlement burned $546 million in short positions in under two weeks. The bears reloaded to even higher levels, and this time the unwind came without a single identifiable headline.

Why the Bears Are Still Crowded

The short thesis on HIMS has real substance, which is exactly why the position got so large. The core argument: Hims lost its highest-margin product line when it agreed to stop selling compounded semaglutide as part of the Novo Nordisk deal. Compounded GLP-1s were sold at a fraction of branded prices with platform-level margins. Now HIMS distributes branded Wegovy and Ozempic as a cash-pay pharmacy partner — a fundamentally different margin profile.

Management guided FY2026 margins to the low-70% range, down from the compounding era. Bears see a company that went from drug-margin economics to distributor economics and think the stock is priced for the old model. And the data breach disclosure — the customer support system was hacked — adds an overhang that has not fully resolved.

But crowded shorts create their own risk. At 46% of float, any positive catalyst becomes an accelerant. Q1 earnings land May 11. If Wegovy distribution numbers beat expectations — CEO Andrew Dudum has targeted 100,000 monthly Wegovy prescriptions — the next squeeze could make this one look tame.

The Bull Case in Three Numbers

The valuation argument for HIMS at these levels is straightforward. Revenue hit $2.35 billion in FY2025, up 59% year-over-year, with 2026 guidance of $2.7–$2.9 billion. The stock trades at roughly 2x forward revenue for a company growing north of 20%. A Seeking Alpha analysis published April 14 argued HIMS trades at bargain EBITDA multiples now that the GLP-1 legal overhang has cleared.

International expansion is the growth vector the market is starting to price. ZAVA and Livewell drove international revenue up 400% to $134 million in 2025, still only 6% of total revenue. The $1.15 billion Eucalyptus acquisition closing mid-2026 adds Australia, Japan, and additional European markets. Management's target is $1 billion in international revenue within three years.

Barclays raised its price target to $29 after the Novo deal cleared the legal overhang, and Needham upgraded to buy with a $30 target. The consensus 12-month target sits at $29.33 across 14 analysts — about 22% above Tuesday's close.

What to Watch

The immediate question is whether forced covering is done or just pausing. At 46% of float and 2.58 days to cover, a 14% move on slightly-above-average volume has not meaningfully dented the short base. If HIMS holds above the 200-week moving average and the $23 breakout level, the squeeze has room to run.

May 11 earnings are the next binary event. The market wants to see three things: Wegovy prescription volume (the 100K monthly target is the benchmark), subscriber retention through the compounding-to-branded transition, and early international contribution from ZAVA markets. Any miss on these gives shorts ammunition to reload.

The perp on Hyperliquid is running hotter than spot — up 19.42% versus 13.88% on the equity — reflecting the leverage and thinner order books typical of HIP-3 markets. That premium is worth watching as a sentiment gauge. If perp funding rates stay elevated, it signals leveraged longs are willing to pay to hold the position, which tends to precede either continuation or a sharp mean reversion.

Trading on Hyperliquid

Trade HIMS on Hyperliquid with up to 10x leverage.